echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Study of Nervous System > JAHA: Efficacy Analysis of Endovascular Therapy in Patients with Acute Ischemic Stroke Disabled Before Stroke

    JAHA: Efficacy Analysis of Endovascular Therapy in Patients with Acute Ischemic Stroke Disabled Before Stroke

    • Last Update: 2021-07-27
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Recently, the heart blood vessels published a research article on the disease areas authoritative magazine JAHA, the study compared the stroke before large vessel occlusion of blood vessels in the treatment of disabled stroke patients (EVT) and medical treatment outcome


    Heart vascular stroke



    The study included a total of 339 patients (237 women; the median age was 85 years [interquartile range (IQR) 79-89]; the median score of the modified Rankin scale before analysis was 3 points [IQR is 2-4]


    thrombus

    28.



    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.